Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
03:57pm, Monday, 17'th Oct 2022 Zacks Investment Research
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults
01:37pm, Friday, 14'th Oct 2022 Zacks Investment Research
GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.
Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review
04:56pm, Thursday, 13'th Oct 2022 Zacks Investment Research
The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023.
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
04:51pm, Thursday, 13'th Oct 2022 Zacks Investment Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.
VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
03:23pm, Thursday, 13'th Oct 2022 Zacks Investment Research
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.
DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study
04:16pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.
Albireo (ALBO) Up on Results From Alagille Syndrome Study
04:03pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.
Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern
02:57pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.
scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval
09:32pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
03:49pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why
05:36pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why
03:03pm, Thursday, 06'th Oct 2022
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
Why Acadia Pharmaceuticals Stock's Rally Could Have Legs
02:19pm, Tuesday, 04'th Oct 2022
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is up 3.3% to trade at $17.60 at last check, as the broader market looks to extend its early October rally.
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
12:44pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
09:47am, Tuesday, 13'th Sep 2022
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
